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 1 
 2 
The Social Logic of Naloxone: 3 
Peer administration, harm reduction, and the transformation of 4 
social policy 5 
 6 
 7 
 8 
 9 
 10 
Abstract: 11 
This paper examines overdose prevention programs based on peer 12 
administration of the opioid antagonist naloxone. The data for this 13 
study consist of 40 interviews and participant observation of 10 14 
overdose prevention training sessions at harm reduction agencies in 15 
the Bronx, New York, conducted between 2010 and 2012. This paper 16 
contends that the social logic of peer administration is as central to 17 
the success of overdose prevention as is naloxone’s pharmacological 18 
potency. Whereas prohibitionist drug policies seek to isolate drug 19 
users from the spaces and cultures of drug use, harm reduction 20 
strategies like peer-administered naloxone treat the social contexts 21 
of drug use as crucial resources for intervention. Such programs 22 
utilize the expertise, experience, and social connections gained by 23 
users in their careers as users. In revaluing the experience of drug 24 
users, naloxone facilitates a number of harm reduction goals. But it 25 
also raises complex questions about responsibility and risk. This 26 
paper concludes with a discussion of how naloxone’s social logic 27 
illustrates the contradictions within broader neoliberal trends in 28 
social policy. 29 
 30 
 31 
Keywords: United States; naloxone; overdose; harm reduction; 32 
public health; drug policy; Bronx; neoliberalism 33 
 34 
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Introduction 1 
 2 
It is widely recognized today that the War on Drugs has not only 3 
failed to reduce drug use in America but has also produced a host of 4 
harmful consequences. In response, alternative strategies are 5 
gaining ground. A major challenge to the prohibitionist consensus 6 
has been mounted by proponents of harm reduction, which seeks to 7 
ameliorate the negative consequences of drug use without 8 
prioritizing abstinence (Marlatt, 1996; Des Jarlais, 1995). Harm 9 
reduction is at once a public health strategy, a dimension of drug 10 
policy, and a health social movement (Brown and Zavestoski, 2004; 11 
Ezard, 2001; Inciardi and Harrison, 1999; Rhodes, 2009). Supporters 12 
of harm reduction have sought above all else to establish that drug 13 
users are “deserving of caring and life rather than punishment and 14 
death” (Small, Palepu and Tyndall, 2006: 74). Far from being a 15 
static and prescriptive program, harm reduction is fluid, reactive, 16 
and evolving, molding itself to the contours of existing drug laws 17 
and treatment options. 18 
 19 
This article examines one of the newest and fastest-growing harm 20 
reduction interventions: peer-administered naloxone, a drug that 21 
reverses the effects of opiate overdose and, when administered 22 
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correctly and in time, can prevent death. Such strategies distribute 1 
naloxone kits and train users to administer the drug to their peers. 2 
Evaluations and meta-analyses of naloxone programs suggest that 3 
they can be effective in preventing drug-related death and may have 4 
other public health benefits (Breedvelt et al. 2015; Giglio, Li and 5 
DiMaggio, 2015; McAuley, Aucott, and Matheson, 2015; Clark, 6 
Wilder, and Winstanley, 2014; Walley et al. 2013; Green, Heimer 7 
and Grau 2008). But most studies of naloxone have been limited to 8 
evaluating its specific medical and public health effectiveness. 9 
Naloxone has not so far received the same critical analysis as other 10 
recent drug policies such as syringe distribution or methadone. The 11 
epistemic, social, and political innovations upon which naloxone 12 
depends, and the complex policy changes wrapped up in the practice 13 
of peer administration, have not yet been fully explored from a 14 
social-scientific perspective. 15 
 16 
Analyzing sessions for training users in administering naloxone on 17 
their peers in the Bronx, New York City, this article investigates the 18 
social logic of naloxone. It argues that peer-administered naloxone 19 
depends not only upon the chemical properties of the drug itself, but 20 
also upon a distinctive approach to the social context of drug use. 21 
Whereas prohibitionist policies seek to isolate users from the spaces 22 
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and cultures of drug use, in contrast, harm reduction strategies like 1 
naloxone see the social networks of drug users as sites and tools for 2 
intervention. As a public health strategy, naloxone depends upon 3 
the experience and expertise gained by users in their careers as 4 
users. This social logic is as central to the success of naloxone as is 5 
the medication’s pharmacological potency.  6 
 7 
The social logic of naloxone facilitates a number of harm reduction’s 8 
political and social goals. In exploiting the experiences and 9 
knowledge gained by those who consume drugs, naloxone 10 
contributes to the destigmatization of users, which is both a means 11 
and an end of harm reduction (Gowan, Whetstone and Andic, 2012). 12 
It formalizes a new relationship between drug users and the state, 13 
affirming users not as criminals or patients but as “indigenous 14 
public health workers” (Bennett et al., 2011) who are part of the 15 
public health project itself. Peer-administered naloxone, like the 16 
harm reduction movement more broadly, seeks to transform users 17 
from passive objects into more active political subjects (Friedman et 18 
al., 2004; Henman et al., 1998). 19 
 20 
But in targeting and exploiting the social worlds of drug use, 21 
naloxone is also representative of recent neoliberal trends in public 22 
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health (Ayo, 2012). In deputizing the user as a public health agent, 1 
naloxone constructs a “responsible subject” charged with the job of 2 
“self-care” (Dean, 1999; Lemke, 2001). While acknowledging that 3 
new forms of surveillance might be the price to pay for access to life-4 
saving resources, some critics have tied the new roles and 5 
responsibilities that emerge with harm reduction interventions like 6 
syringe exchange or naloxone to new forms of discipline of deviant 7 
populations (Bourgois, 2000; McLean, 2011; Moore, 2004; Roe, 8 
2005). Yet, as Gowan, Whetstone and Andic (2012) argue, not all 9 
social policies that promote responsibilization should necessarily be 10 
seen as antithetical to social rights. “To the contrary, if such 11 
attempts simultaneously foster recognition of a collective, or 12 
relational, selfhood, they may create the preconditions for claims to 13 
social citizenship” (Gowan, Whetstone and Andic, 2012: 1258). The 14 
case of naloxone points to these sorts of conflicting potentials within 15 
contemporary social policy. 16 
 17 
The questions are how, why, and to what ends particular policy 18 
logics are used, not merely whether they are used. Peer 19 
administration requires rethinking the subjects and objects of public 20 
health strategies. Leveraging the expertise of drug users forces a 21 
reevaluation of their life experiences. The ways in which users are 22 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
6 
 
charged with administering drugs on others and thus with life-1 
saving power decenters the authority of credentialized medical 2 
professionals, and raises complex questions about risk and 3 
responsibility. The social logic of naloxone therefore speaks to more 4 
general issues regarding the politics of social and public health 5 
policy today. As social interventions and network-based thinking 6 
become more common in social policy and the “new public health” 7 
(Petersen and Lupton, 1996), these issues have broader relevance. 8 
 9 
Site and Methods 10 
 11 
This article adopts a qualitative and ethnographic approach to 12 
studying social policy (see Stevens, 2011; Schatz, 2009: Yanow, 13 
1996; Spradley, 1970). Using participant observation and 14 
interviewing, this approach relies upon “in-depth fieldwork… in 15 
order to analyze the concrete practices through which a policy is 16 
enforced in everyday life” (Dubois, 2009: 222). The goal is to 17 
examine the relational and iterative dimensions of policy formation 18 
and implementation, and to interpret the meanings and taken-for-19 
granted categories that policies rely upon and operationalize. 20 
Critical policy ethnographies also connect the policy process to 21 
broader political-economic changes (Fischer, 2016). This approach is 22 
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therefore well suited to interpreting recent trends in overdose 1 
reversal, evaluating the assumptions upon which this form of policy 2 
relies, describing the techniques that it mobilizes, and explaining its 3 
relation to the broader context of neoliberal public health policy. 4 
 5 
Data for this study were gathered over a two-year period from 6 
January 2011 to December 2012, as part of a larger study on the 7 
diffusion and institutionalization of harm reduction in New York 8 
City. Fieldwork involved participant observation at three syringe 9 
exchanges in the Bronx and 40 semi-structured interviews with 10 
agency staff and peer volunteers, employees of the New York City 11 
Department of Health and Mental Hygiene (DOHMH), the New 12 
York State AIDS Institute, and harm reduction advocates working 13 
at three New York City harm reduction and drug policy 14 
organizations. Participants were recruited based on their positions 15 
within these organizations or other involvement with naloxone 16 
training. After explaining the nature and purpose of the research, 17 
verbal informed consent was obtained from each interviewee. 18 
Fieldwork also included observation of ten overdose prevention 19 
trainings, a majority of which (N=8) took place at a syringe 20 
exchange here referred to as South Bronx Harm Reduction 21 
(SoBroHR). In addition to trainings aimed at active drug users, 22 
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naloxone training for staff of New York City-area social service 1 
agencies were also observed (N=2). In accordance with Institutional 2 
Review Board protocol, names of the organizations have been 3 
changed and interviewees are here referenced with randomly 4 
selected initials. 5 
 6 
Opioid overdose fatalities have nearly quadrupled since 1999, and 7 
are now the leading cause of accidental death in the United States. 8 
An estimated 91 Americans die every day from an opioid overdose 9 
(Rudd et al. forthcoming). In line with national trends, overdose has 10 
become a leading cause of death in New York City (see Piper et al., 11 
2007, 2008). Heroin overdose more than doubled between 2010 and 12 
2013, and overdose from opioid analgesics rose by 256% between 13 
2000 and 2013 (DOHMH, 2014: 3; Siegler et al., 2014). The South 14 
Bronx, where data for this study were collected, has persistently had 15 
the highest rate of opiate overdose in the city (DOHMH, 2011).  16 
 17 
The South Bronx is also home to some of the city’s oldest and most 18 
established harm reduction agencies. These agencies grew out of the 19 
work of activists who initiated underground syringe distribution in 20 
the early 1990s in response to the HIV/AIDS crisis. Overtime, 21 
activist groups professionalized and began offering harm reduction 22 
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and other health services in partnership with City and State health 1 
departments. Today, SoBroHR provides a variety of programs and 2 
services to its more than three thousand participants, including 3 
syringe exchange, case management, employment training, onsite 4 
primary health care and pharmacy, soup kitchen, showers, laundry, 5 
and social space. More than just a needle exchange, SoBroHR is a 6 
service provider and community space that has come to play a vital 7 
role in the “geography of survival” (Mitchell and Heynen, 2009; 8 
McLean, 2012) of many of it homeless and drug using participants.  9 
 10 
SoBroHR was one of the first agencies in the city to offer overdose 11 
reversal training and access to naloxone. In 2005, New York passed 12 
legislation authorizing opioid antagonist administration programs, 13 
and the state health commissioner established standards for 14 
overdose prevention programs and the use of naloxone by non-15 
medical personnel. Naloxone programs are now licensed by the 16 
NYSDOH and abide by the regulatory framework set out by the law 17 
(Beletsky, Burris and Kral, 2009). As HIV/AIDS rates among 18 
injection drug users have declined, established agencies like 19 
SoBroHR with deep roots in the community have been instrumental 20 
in developing programs for overdose prevention as a new epidemic 21 
has taken hold.  22 
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Naloxone as a Harm Reduction Strategy 1 
 2 
Before the development of formalized overdose reversal programs, 3 
drug users engaged in various do-it-yourself strategies to prevent 4 
overdose death. Improvised folk remedies like placing ice on genitals 5 
or injection of concentrated saline were largely ineffective and often 6 
dangerous (Beschner and Bovelle, 1985: 93-97; Maxwell et al., 2006: 7 
89-90). And though overdose has long been a common and tragic fact 8 
of life among opiate users, it was not until the late 1990s and early 9 
2000s that activists in Chicago, San Francisco, New York, and 10 
elsewhere began to develop naloxone-based overdose reversal as a 11 
core harm reduction strategy. 12 
 13 
Naloxone hydrochloride—also known by the brand name Narcan—is 14 
an opiate-blocking drug that reverses the effects of overdose by 15 
counteracting the depression of the central nervous and respiratory 16 
systems that can cause death. Patented in 1961 and promoted in the 17 
1960s as a possible replacement for methadone (Zaks et al., 1971), 18 
naloxone quickly became important in the treatment of accidental 19 
opiate overdose within clinical settings. It is effective on all types of 20 
opiate overdose, from heroin to prescription pharmaceuticals like 21 
oxycodone and fentanyl. Naloxone has an unscheduled regulatory 22 
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classification, meaning that it has no addictive or psychoactive 1 
properties and thus no potential for abuse. Serious adverse affects 2 
are rare and naloxone will have no effect on non-opiate users 3 
(Buajordet et al., 2004). Typically, the drug takes effect within a few 4 
minutes and lasts from thirty minutes to two hours depending on 5 
the dose administered and the amount of opiates present in the 6 
body. 7 
 8 
Despite its lifesaving potential, naloxone’s use as a harm reduction 9 
tool was not immediately obvious. As typically practiced by 10 
paramedics, intravenous administration of a high dose of naloxone 11 
rapidly strips the body of opiates, which is the functional equivalent 12 
of throwing a dependent user into sudden and violent withdrawal. 13 
As Chicago Recovery Alliance (CRA) member Dan Bigg notes: “For 14 
those who had heard about naloxone, it was generally as kindly as 15 
garlic might be to a vampire” (Harm Reduction Coalition, n.d.). 16 
Underscoring the connection between naloxone and punitive war-on-17 
drugs-style policy, KR, an addictions researcher and user-activist, 18 
reported a widely circulating rumor that police would inject 19 
suspected users with naloxone in order to consider the appearance of 20 
withdrawal symptoms as justification for arrest. Naloxone, then, 21 
was widely known but not immediately adopted as part of the 22 
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common practice of users. Naloxone’s successful use as a public 1 
health tool required the development of a strategy attuned to the 2 
social contexts of drug use and overdose. 3 
 4 
It has long been recognized that people use drugs within a social 5 
context (Becker, 1953; Young, 1971; Latkin et al, 1995). But the 6 
politics of addiction and punishment that surround drug use has 7 
tended to see this social context as the root of the problem. 8 
Prohibitionist approaches are based on the assumption that the 9 
social settings of drug use and social connections between users are 10 
wholly negative, nothing but spurs to drug consumption and crime 11 
that should be avoided. Early progressive drug policy also sought to 12 
separate drug users from their social environments, typically 13 
incarcerating city-dwellers in rural ‘drug farms,’ where it was hoped 14 
that hard work and a healthy diet would cure the social, moral, and 15 
physical deficiencies of the ‘addict’ (Campbell, Olsen and Walden, 16 
2008). The drug farms were short lived, but the underlying 17 
assumption about the corrosive nature of drug users’ networks 18 
remained and became the blueprint for the residential model that 19 
continues to dominate the American drug treatment industry today.  20 
 21 
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Turning the notion of social contagion on its head, peer-to-peer 1 
administration is the major innovation that underpins the 2 
successful public health application of naloxone. The practice of peer 3 
administration transformed naloxone from an unwelcome 4 
intervention imposed by unsympathetic emergency medical 5 
personnel into a symbol of drug user self-help and mutual aid. The 6 
idea of peer-administered naloxone was developed by user-activists, 7 
front-line medics, and other supporters of earlier harm reduction 8 
strategies. Just as syringe exchange originated as a direct, 9 
pragmatic response to the HIV/AIDS crisis among injectors, 10 
naloxone’s extra-clinical trajectory also began as an emergency 11 
response to a deadly problem. The CRA began its work in 1996 in 12 
response to the overdose death of activist John Szyler. Medics 13 
working with the CRA began dispensing naloxone directly to select 14 
participants (Maxwell et al., 2006), paving the way for the adoption 15 
of naloxone by user-activists and their allies. 16 
 17 
The earliest naloxone pilot programs distributed the drug to users in 18 
pairs who would be responsible for each other (Seal et al., 2005: 19 
304). However, restricting naloxone prescriptions to established 20 
pairs proved impractical and it quickly became clear that another 21 
model was needed. Examining the structure of syringe circulation 22 
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within user social networks, one group of researchers identified “the 1 
existence of ‘hubs’ or ‘nodes’ of experience and knowledge within 2 
drug-using communities which appear to be recognized by users and 3 
their peers” (Bennett et al., 2011; See also Marshall et al., 2015). 4 
Naloxone supporters adopted this insight. The hope was that “[o]nce 5 
naloxone rescue kits are distributed into the community to people 6 
trained in overdose prevention, they are further disseminated 7 
through social networks to people who were not trained directly by 8 
the distribution programs” (Doe-Simkins et al, 2014). The very 9 
structure of once-maligned user networks is now seen as a tool to 10 
amplify the effectiveness of public health policies.  11 
 12 
The goal was for nodal individuals to serve not only as the point of 13 
entry for public health interventions but also as the agents of those 14 
interventions. Bennett et al. (2011), drawing on Giblin (1989), 15 
understand peers in harm reduction as “indigenous public health 16 
workers”: non-credentialed, informally trained participants who are 17 
deputized to perform public health work. The emergence of peer 18 
work in harm reduction is a way to overcome the distance between 19 
users and the formal health system, which often cooperates with the 20 
same punitive state that punishes and stigmatizes users (Dechman, 21 
2015). It also reflects the restructuring of social services, which 22 
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increasingly emphasize participation and the “buy-in” of recipients 1 
(Martin, 2008). Users have credibility among each other that 2 
outsiders and professionals generally lack. And indigenous public 3 
health workers, unlike most of their formally-credentialed 4 
counterparts, are familiar with the spaces and routines of drug use. 5 
 6 
By training users to administer naloxone on one another, overdose-7 
reversal drugs can be deployed precisely when and where overdose 8 
occurs by people familiar with the experience of drug use who are 9 
able to draw on local knowledge. According to the Harm Reduction 10 
Coalition (HRC), between 1996 and 2013, over 152,000 laypersons 11 
have been provided with training and naloxone kits. Of these 12 
recipients, 81.6% were characterized as drug users, while 11.7% 13 
were family and friends and 3.3% were service providers (Wheeler et 14 
al., 2015: 631-632). These figures suggest that drug users 15 
administering naloxone on their peers, and not health professionals, 16 
are the central agents of this strategy. 17 
 18 
Mobilizing Peers 19 
 20 
Peer-administered naloxone depends upon the existence of drug 21 
users who can act as peers. Users become peers after attending 22 
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training sessions and being issued naloxone by a person with 1 
prescribing authority. These training sessions, which are required 2 
by law and typically occur at syringe exchanges, provide more than 3 
just instructions on how to deploy naloxone on an overdosing body. 4 
They are also occasions for fostering a new, active role for users 5 
within their social networks. 6 
 7 
Overdose prevention training takes place every day at SoBroHR. 8 
Training sessions are part of a roster of groups that participants can 9 
attend. Participation in these groups is incentivized by the 10 
distribution of a round-trip MetroCard, at the time worth $4.50. 11 
There is no limit to the number of times an individual participant 12 
can sign up for an overdose prevention group, and indeed many 13 
attendees are regulars.  14 
 15 
Training sessions are short, lasting up to thirty minutes, and 16 
typically include about fifteen participants and one trainer. 17 
Instruction can take place in English or Spanish, and though a set 18 
curriculum is repeated each time, conversations vary according to 19 
the experience of participants. These sessions are often the only 20 
instruction that participants receive when they take on the peer 21 
role. Upon completion, participants are given a prescription for 22 
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naloxone and a kit containing two vials of the drug and either two 1 
syringes or atomizers, first aid equipment, and written instructions. 2 
Training sessions can be conducted by peers, agency staff, or others, 3 
though only physicians or licensed physicians’ assistants have 4 
prescribing authority.  5 
 6 
Based upon pre-existing relationships within user social networks, 7 
the peer role was formalized in order to meet multiple objectives. 8 
For some, overdose prevention training is a way to improve the lives 9 
of users generally. NR, a veteran harm reduction activist, sees 10 
naloxone as all about “recognizing that you need to put tools in the 11 
hands of drug users so they can have autonomy over their drug use.” 12 
For others, being trained as a peer offers a sense of purpose that 13 
users are often denied. VU started as a participant at SoBroHR and 14 
went from peer to member of staff. 15 
VU: When I first got here, I didn’t feel out of place. 16 
What I did feel was included in the process. 17 
Everywhere during the time I was using, that was 18 
something that was stigmatized. That I was a drug 19 
user, all the behaviours that I went through. I was 20 
excluded from many places. So when I got here, and 21 
they included me, that was very significant to me.  22 
 23 
CT, a peer program coordinator at another harm reduction agency, 24 
offers similar observations. For her, mobilizing peers is a way “for 25 
disenfranchised communities to have some sense of belonging.” 26 
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CT: It serves as somewhat of a motivation to get people 1 
interested in not just doing outreach but being aware of 2 
the communities that they’re serving and those social 3 
networks that happen with people, and what it looks 4 
like to become more political. 5 
 6 
For CT, overdose reversal is part of a larger harm reduction ethic. 7 
Other peers see being ready to administer naloxone as a way to 8 
“give back” to the harm reduction community itself. LW is a peer 9 
and member of SoBroHR’s participant advisory board: 10 
LW: It’s taught me a lot. It’s taught me to be 11 
responsible. And the only way I can give back is what 12 
I’m doing now... I’m just a participant, peer, whatever, 13 
but I take so much pride in coming in to SoBroHR. 14 
 15 
Other participants also come to strongly identify with the naloxone 16 
project. A fieldnote excerpt describes RI, a regular at SoBroHR for 17 
whom involvement with naloxone is a major part of the presentation 18 
of self: 19 
RI is a tall Latino man in his mid-thirties. He has short 20 
black hair and a rigid posture. He strides through 21 
SoBroHR with an air of familiarity and authority. He 22 
attends all of the naloxone training sessions, often 23 
volunteering to act out the role of overdoser. He wears 24 
a naloxone kit around his waist, the blue pouch 25 
dangling from his belt like a janitor’s key ring. 26 
 27 
User activists and their allies claim naloxone as tool of 28 
empowerment. The peer role offers users the possibility of authority 29 
and respect in a world that often denies it to them. 30 
 31 
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Also in line with harm reduction’s ethos, training sessions are 1 
organized in ways that foster participant-led dialogue. Trainers do 2 
not emphasize the status differences between themselves and the 3 
peers. They seek to facilitate discussion with and among peers, 4 
encouraging attendees to use training sessions as spaces to share 5 
their personal experiences. Repeatedly returning to training 6 
sessions long after they have mastered the technical information 7 
necessary for properly administering naloxone, peers use sessions to 8 
share “war stories” about overdoses they have experienced or 9 
witnessed, and to remember friends they have lost. Trainees also 10 
critically reflect upon naloxone itself. At one session at SoBroHR, a 11 
peer remarked, “I know some people who would actually be very 12 
angry if you administered Narcan…. Knocks the heroin right out of 13 
them,” leading to a longer conversation about the ethical and 14 
practical dilemmas of naloxone administration. Naloxone training 15 
sessions are opportunities to collectively face some of the 16 
challenging questions that pattern many users’ lives: the everyday 17 
threat of overdose and death, the complexities of overdose reversal, 18 
and the possibility of redemption and transformation. 19 
 20 
In a process driven at once by public health workers and by 21 
participants, the peer role has developed into an instrument of 22 
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public health policy. By adjusting the peer’s sense of self as an active 1 
moral agent, naloxone supporters hope that participating in 2 
overdose prevention will have a broader set of positive effects. KR, a 3 
prescribing physician noted, “Actually, my personal view of it is that 4 
the person doing it, the person reviving the other person may be the 5 
person most likely to go into treatment.” Peers are trained as 6 
indigenous public health workers capable of intervening in overdose. 7 
But naloxone supporters hope that peers will have a wider impact 8 
on their communities, on the public perception of users, and on 9 
themselves. 10 
 11 
Expertise and Experience 12 
 13 
Among all objectives, however, the predominant purpose of training 14 
sessions is to educate peers so that they are prepared to administer 15 
naloxone. Training programs vary between locations but a core 16 
curriculum developed with the input of the HRC includes basic 17 
opioid neurophysiology; pharmacodynamics and pharmacokinetics of 18 
opiates and of naloxone and other opiate antagonists; risk factors 19 
and prevention techniques for opiate overdose; signs and symptoms 20 
for the early recognition of overdose; prevention of choking and 21 
aspiration in unconscious patients; techniques of rescue breathing; 22 
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routes of administration and dosing guidelines for naloxone; and 1 
protocols for follow-up care (Maxwell, 2006).  2 
 3 
Learning to administer naloxone requires mastering a broad 4 
amount of practical and technical knowledge. Properly 5 
administering naloxone requires knowing how to recognize that an 6 
overdose is occurring; how to manoeuver an unresponsive body into 7 
the recovery position in order to reduce the risk of choking and to 8 
optimize airflow; determining whether or not naloxone is even 9 
appropriate given the specific substances that have been ingested; 10 
how to use syringes and other medical paraphernalia in a highly 11 
time-sensitive, life-and-death situation; and how to respond to 12 
possibly violent people experiencing drug withdrawal symptoms. 13 
Few public health initiatives place this level of responsibility in the 14 
hands of non-specialists. 15 
 16 
An excerpt from a training session demonstrates the high level of 17 
practical and technical knowledge that peers are asked to master. 18 
The session excerpted here was led by NK, a physician’s assistant, 19 
in conversation with MP, who is a regular training session attendee.  20 
NK: So if you’re going to give them an intramuscular 21 
dose, you’ve got two bottles like this, and two syringes. 22 
One syringe for each bottle. You only have to use the 23 
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syringe once. You’re not looking for a vein, it’s 1 
intramuscular. 2 
MP: You can hit the leg or no? 3 
NK: You can hit the leg. The next step… these are 4 
single dose vials, so use the whole bottle, you don’t 5 
have to worry about measuring. And there’s not very 6 
much in here. It’s 1 CC, so the bottle looks like it’s 7 
almost empty. Don’t be alarmed. You just want to get 8 
everything that’s in the bottle into the syringe. And to 9 
help you do that, it helps to put some air into the bottle 10 
first. So open up your syringe, get a CC of air into there. 11 
And then, the bottles have a little orange top on them. 12 
Pull the top off, and then there’s a little rubber stopper. 13 
Just put the needle right through the stopper, just so 14 
you can see the point sticking out at the top. Then we 15 
can push the air in, the pressure will start to push it 16 
out by itself. If the needle’s too high, you’ll start to get 17 
air, so if you’re getting air and there’s still liquid left in 18 
the bottle, push the air back out, pull the needle down 19 
so it’s under the surface, just so you can see the tip 20 
sticking out, and then pull the rest in. Just get as much 21 
in as you can, every drop. And then any air left in the 22 
needle, push it out. And then you’re ready to go.  23 
 24 
As this excerpt makes clear, peers who participate in naloxone 25 
interventions are asked to perform complex actions, requiring 26 
attention to detail and a technical facility with medical equipment. 27 
Peers must make sophisticated medical decisions, drawing upon 28 
knowledge gleaned from training sessions as well as practical 29 
knowledge learned from experience with drugs use. 30 
 31 
Once medical equipment has been prepped, the peer needs to 32 
administer naloxone through injection into the body of the person 33 
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who is overdosing. Peers need to know where on the body is best for 1 
the medicine to be absorbed quickly.  2 
MP: What about the butt cheek? 3 
NK: Not the butt cheek. Don’t go in the butt. One, 4 
that’s where the most fat is. And you want to go under 5 
the fat, into the muscle. So you got a guy with a lot of 6 
body fat, don’t be afraid to go deep. Cause you want to 7 
get underneath the fat. The muscle has all the 8 
circulation.  9 
MP: What happens if the person is thin? 10 
NK: Thin? It’s not going to go that far, if you go too far 11 
you’re going to hit bone. Can’t go further than bone. 12 
You want to go straight in. Cause that’ll get you to the 13 
muscle the quickest. If they’re skinny, it’s not going to 14 
go all the way. You can actually kind of feel cause your 15 
muscles are surrounded by a thick membrane, so as 16 
you go in, you might feel it resist a little bit and then 17 
pop through. Then you know you’re in the muscle. You 18 
want to go in straight, don’t be afraid to go deep, like a 19 
dart. Stick it in, push all the medicine in, and then, 20 
when you’re done… 21 
MP: Get ready to run! 22 
 23 
Peers are tasked with making significant decisions about when, 24 
where, and how to administer naloxone. They draw upon their own 25 
knowledge in order to be comfortable manipulating a body in a 26 
moment of acute medical crisis. They represent the leading edge of 27 
the medical apparatus, administering emergency medical care until 28 
medics can arrive.  29 
 30 
Naloxone training sessions build upon the significant expertise that 31 
drug users develop in their careers as users. Another fieldnote 32 
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excerpt describes a typical meeting of an overdose prevention 1 
training group at SoBroHR.  2 
NK: So what are the different kinds of opiates? 3 
[Crowd calls out long list of different forms of opiates, 4 
including heroin, methadone, oxycodone, hydrocodone, 5 
morphine, codeine, Vicodin, Percocet, Xolox, Dilaudid, 6 
Fentanyl, Demerol, etc.] 7 
DS: Opioids is made to work on the same receptors as 8 
the opiates. 9 
NK: Right. Besides opiates, there’s completely 10 
synthetic medicines, like Fentanyl is one, methadone is 11 
one, those are all made in the laboratory. 12 
DS: Suboxone is an opiod.  13 
NK: Right, right. Opioids are opiates, so they’re both 14 
natural opiates, from the opium poppy, and synthetic 15 
ones. 16 
FE: Mmmhm. 17 
DS: I know medicine, man, I know medicine. 18 
NK: So again, those are the drugs that Naloxone works 19 
on. It doesn’t work on, in particular, the benzos, the 20 
benzodiazepines. So what are some of those?  21 
Group: Xanax, Klonopin, Librium, Ativan… 22 
FE: What about Catapres? 23 
NK: No, Catapres isn’t a benzo, but it also doesn’t work 24 
with this. It’s something that you could potentially 25 
overdose on.  26 
DS: It’s not a benzo, but it works like one, boy. You 27 
take a Catapres with some dope or whatever… 28 
 29 
The attendees have deep knowledge about opiates already, acquired 30 
well before they began their training sessions. They know the 31 
difference between opiates and opioids, they can identify 32 
benzodiazepines, and they have an understanding of the biochemical 33 
differences between different classes of drugs and their effects on 34 
the body. 35 
 36 
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Peers use training sessions to exchange specific medical information 1 
drawn from their experiences. For example, participants share hard-2 
won wisdom about the strength of certain branded batches of heroin, 3 
warnings about the relative potency of fentanyl and other 4 
pharmaceuticals, and advice about which combinations of 5 
substances were particularly effective or lethal. The trainers 6 
encourage this kind of knowledge transfer, and invite participants to 7 
explain and demonstrate various components of the training 8 
curriculum. 9 
 10 
Far from treating users as passive objects of policy intervention, 11 
then, naloxone draws on the relatively high degree of medical 12 
knowledge that exists, in its own distinct forms, within the cultures 13 
of drug user networks. Overdose reversal would be impossible 14 
without precisely those practices, knowledges, and skills that are 15 
stigmatized in prohibitionist drug policies: facility with needles, 16 
experience with drug interactions, comfort and familiarity in the 17 
social spaces of drug use. Users can act as competent reversers of 18 
overdose only because they possess this taboo form of expertise. 19 
Only users themselves have the requisite combination of vernacular 20 
medical knowledge and familiarity with the routine situations of 21 
drug use. As NK observed, “I mean there’s a cultural thing. People 22 
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who have experience with needles are fine with it.” Subsequent 1 
research confirms that this form of user expertise is effective in 2 
emergency situations. One study found that “people trained in 3 
overdose recognition and naloxone administration were comparable 4 
to medical experts in identifying situations in which an opioid 5 
overdose was occurring and when naloxone should be administered” 6 
(Green, Heimer and Grau, 2008: 984). This effectiveness is due 7 
precisely to users’ expertise. In abandoning the prohibitionist 8 
insistence on stigmatizing the experience of the user, harm 9 
reduction strategies like naloxone have identified a potent public 10 
health resource.  11 
 12 
Risk and Responsibility 13 
 14 
In utilizing the networks, experience, and expertise of drug users, 15 
naloxone also creates new relationships between users and medical 16 
authorities. While naloxone distribution continues to rely on various 17 
medical experts, the general impact of the peer-to-peer model is to 18 
diminish the central authority of the physician in the provision of 19 
life-saving care. This process raises new questions about 20 
responsibility, liability, and authority.  21 
 22 
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Naloxone training sessions make clear that peer administration 1 
does carry with it a number of risks. Recipients risk nerve damage 2 
from a misplaced injection, among other possible injuries. 3 
Administrators risk exposure to blood and other potentially 4 
biohazardous fluids, and the violence of people who “wake up 5 
swinging.” The significance of these risks tends to be downplayed by 6 
naloxone supporters. Informants involved in naloxone programs 7 
were unanimous in asserting that the risks of injury or harmful side 8 
effects are minimal. When questioned about the possible risks of a 9 
botched naloxone administration, FW, a physician involved with 10 
naloxone programs reported, “The only thing that could go horribly 11 
wrong is that the person dies anyway.” The assumption is that 12 
anyone who needs naloxone would otherwise experience fatal 13 
overdose; hence, to a greater extent than in most other areas of 14 
medicine and social policy, routine rules are suspended. 15 
 16 
Peer administration is at the core of naloxone programs but it 17 
clashes with traditional lines of medical authority. Peers receive 18 
prescriptions at the end of training sessions, but naloxone is not 19 
intended for use on the person for whom the prescription is written. 20 
Instead, naloxone is administered by the prescription-holder on a 21 
third party whose identity has not been predetermined by the 22 
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prescribing authority and about whom no prior knowledge is 1 
available. The prescription-holder might have a longstanding 2 
relationship with the person on whom they administer naloxone, 3 
where medical history, risk, and consent could conceivably have 4 
been discussed—or they might be complete strangers where none of 5 
these issues could possibly have been addressed.  6 
 7 
The questions regarding responsibility and liability significantly 8 
structure access to and support for naloxone. FW, the physician who 9 
was involved in the development of naloxone programs in New York 10 
recalled: 11 
FW: The law holds the person administering naloxone 12 
harmless. And it holds the programs harmless. It 13 
doesn’t hold the prescribers harmless, they tried to 14 
make them harmless but they didn’t make it through 15 
the code committee on the state level. So liability and 16 
malpractice is still somewhat of a disincentive to 17 
physicians who want to get involved in prescribing 18 
naloxone. So liability is not decided. Malpractice 19 
companies haven’t looked closely at the naloxone 20 
program. There hasn’t been a test case. 21 
 22 
 23 
The uncertain legality of peer-administered naloxone distribution 24 
continues to be the most important barrier to wider participation by 25 
physicians, even though legislation has been passed shielding them 26 
from liability. 27 
 28 
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Even after questions of legal liability have been settled, the move 1 
from physician to peer administration seems to some to threaten 2 
traditional forms of medical authority. A naloxone trainer described 3 
this position: 4 
NK: One of the big barriers is I think because it sort of 5 
breaks the professional barriers, and I think that's why 6 
in some ways a lot of the resistance is coming from 7 
MDs… They like being the gatekeepers for control of 8 
this stuff. 9 
 10 
For this reason, many harm reduction advocates see doctors as 11 
opponents of peer-administered naloxone. This conflict over the 12 
gatekeeping function of medical decision-making is part of the 13 
broader politics of harm reduction. But because of questions 14 
surrounding prescribing authority, it is particularly acute with peer-15 
administered naloxone. 16 
 17 
Ultimately, peer-administered naloxone is only one part of the 18 
public health response to overdose. Even trained peers must 19 
continue to interact with the formal medical system. It is important 20 
that emergency medical services be called after administering 21 
naloxone, as the overdoser is still at risk of lapsing back into 22 
overdose and may experience other symptoms associated with opiate 23 
withdrawal. Many users fear summoning emergency responders, as 24 
doing so often means police involvement, which could lead to arrest. 25 
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This may be the most serious obstacle to naloxone’s success 1 
(Brodrick, Brodrick, and Adinoff 2016). A Good Samaritan Law was 2 
passed in 2011 to address this fear (see Drug Policy Alliance n.d.), as 3 
were other immunity laws enabling the practice of medicine without 4 
a license. But many would-be peer administrators remain 5 
apprehensive. One of the DOHMH harm reduction staffers 6 
explained: 7 
CG: I'm all about getting more naloxone into the hands 8 
of more people. The problem with naloxone is as it 9 
stands right now, it's coupled with education. And that 10 
education piece is really important. So how do you talk 11 
to people about the risks of an overdose and how you 12 
actually use naloxone. If you can just buy it off the 13 
shelf at a pharmacy, it's not clear that somebody's 14 
going to A, use it in the right circumstance, B, use it in 15 
the right way, C, still call 911, which is crucial and 16 
that's the biggest thing that we educate people about. 17 
Call 911, then give the naloxone. Whatever you do, you 18 
still have to call 911.  19 
 20 
There is no legal mechanism to require drug users to call emergency 21 
medical services. The administration of naloxone, and the 22 
summoning of help, is at the observer’s discretion. In transferring 23 
responsibility onto users to administer life-saving drugs to their 24 
peers, naloxone also transfers a number of risks: the risk of harm, 25 
the risk of death, the risk of entanglement within the legal system 26 
which has a still-evolving relationship to peer-administered services 27 
for drug users. Naloxone programs evidently cannot occur without 28 
transferring authority to users, but in doing so, they raise a number 29 
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of questions that, at least in New York City, remain largely 1 
unanswered.  2 
 3 
Discussion and Conclusion 4 
 5 
This paper has argued that in order to function as a public health 6 
strategy, peer-administered naloxone overdose prevention programs 7 
rely upon a distinctive social logic. Breaking with the War on Drugs 8 
paradigm that warns against peer influence, overdoes prevention 9 
mobilizes peers as indigenous public health workers. Such programs 10 
exploit, rather than seek to erase, the social connections, tacit 11 
knowledge, and specific expertise that users acquire as users. This 12 
social logic has enabled naloxone to succeed and fueled its growth as 13 
a public health strategy. But it also raises difficult questions about 14 
responsibility and risk. Users are tasked with saving the lives of 15 
their peers, asked to carry out technically advanced public health 16 
work without any remuneration—and with no established 17 
consequences if they fail. 18 
 19 
It is clear that the social logic of naloxone has both medical and 20 
political motivations. Public health departments came to recognize 21 
that medical interventions that did not overcome the alienation that 22 
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users experience at the hands of the formal health system were 1 
bound to fail. Revalorizing the life experiences of the drug user was 2 
the only way to effectively intervene to stem the overdose crisis. 3 
Because it looks to users themselves as experts, naloxone revalues 4 
the experience of marginality. It forges new coalitions between 5 
medical researchers, law enforcement, public health administrators, 6 
and drug users activist groups in order to pursue progressive goals. 7 
By integrating drug users as users into political society, this form of 8 
drug policy potentially provides new avenues for participation, 9 
solidarity, and citizenship. 10 
 11 
In empowering users as health workers, naloxone assumes and 12 
bolsters neoliberal trends in social policy. Critical analysts of harm 13 
reduction like Bourgois (2000), Roe (2005), and McLean (2011) have 14 
connected harm reduction’s emphasis on self-care with the 15 
neoliberal drive towards responsibilization, where individuals are 16 
burdened with responsibilities—such as the protection and 17 
preservation of life—that had previously belonged to the state and 18 
other collective institutions. This study suggests that in many ways, 19 
naloxone is consistent with this story. Naloxone prioritizes 20 
pragmatic interventions while remaining agnostic towards the 21 
structural causes of social suffering. These programs depend upon 22 
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decentralizing authority and redistributing accountability towards 1 
individuals and self-organized communities. At least in the 2 
American context, peer-administered naloxone is in fact unthinkable 3 
without the transformations in public health associated with 4 
neoliberalism. 5 
 6 
But the case of naloxone complicates this line of criticism. Peer-7 
administered overdose reversal suggests that decentralization, 8 
deputization, and responsibilization can be compatible with projects 9 
for collective dignity, autonomy, and mutual aid. It is arguably an 10 
example of what James Ferguson sees as a policy that exploits 11 
typical “neoliberal moves” (Ferguson, 2009: 174) for progressive 12 
ends. Rather than seeing naloxone as an example of the imperative 13 
to discipline and control, it may be more fruitful to see it as a public 14 
health innovation that has managed to prevail in the era of 15 
austerity and privatization in part by harnessing neoliberal 16 
techniques towards different goals. Rather than denying the 17 
existence of social networks or destroying them through 18 
commodification, naloxone seeks to use and strengthen them. 19 
 20 
Peer-administered naloxone thus points to the complexity of 21 
contemporary developments in social policy and public health. It 22 
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demonstrates that in a time when the state is absolving itself of 1 
traditional responsibilities for the care of citizens, some new 2 
opportunities for progressive policymaking are emerging. Amid a 3 
broader shift towards privatization, the case of peer-administered 4 
naloxone suggests there are also new ways for policy to become 5 
social. 6 
 7 
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Highlights 
 
• Peer administered naloxone relies on social dynamics of drug use 
• Drug users’ expertise leveraged to pursue public health aims  
• Peer administration raises questions about risk and responsibility 
• Drug users gain new role as indigenous public health workers 
• Peer administered naloxone example of public health policy in a neoliberal era 
 
